Clinical Trial: Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy
Brief Summary: The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
Detailed Summary:
Sponsor: Sirion Therapeutics, Inc.
Current Primary Outcome: GA lesion progression [ Time Frame: 1 year ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Sirion Therapeutics, Inc.
Dates:
Date Received: January 30, 2007
Date Started: December 2006
Date Completion:
Last Updated: June 21, 2010
Last Verified: June 2010